Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$131.78
0.030.02%
Pre-Market: 6:06 PM EDT
Comments
Loading...
Intra-Cellular Therapies Analyst Ratings and Price Targets | NASDAQ:ITCI | Benzinga
Intra-Cellular Therapies Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Intra-Cellular Therapies Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
Canaccord Genuity
RBC Capital
Piper Sandler
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Intra-Cellular Therapies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/24/2025 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $140 → $132 | Downgrade | Outperform → Neutral | Get Alert |
| 02/21/2025 | Buy Now | — | Needham | Ami Fadia62% | — | Reiterates | Hold → Hold | Get Alert |
| 01/31/2025 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $119 → $132 | Downgrade | Buy → Hold | Get Alert |
| 01/22/2025 | Buy Now | — | RBC Capital | Brian Abrahams52% | $108 → $132 | Downgrade | Outperform → Sector Perform | Get Alert |
| 01/14/2025 | Buy Now | — | Piper Sandler | David Amsellem69% | $107 → $132 | Downgrade | Overweight → Neutral | Get Alert |
| 01/13/2025 | Buy Now | — | Needham | Ami Fadia62% | $100 → $100 | Downgrade | Buy → Hold | Get Alert |
| 11/04/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $81 → $89 | Maintains | Overweight | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Ami Fadia62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | — | Needham | Ami Fadia62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Morgan Stanley | Jeffrey Hung56% | $92 → $95 | Maintains | Overweight | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $106 → $108 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $130 → $130 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $130 → $130 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | — | Piper Sandler | Charles Duncan73% | $68 → $92 | Upgrade | Neutral → Overweight | Get Alert |
| 08/21/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $79 → $81 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $107 → $106 | Maintains | Outperform | Get Alert |
| 08/08/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $120 → $130 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | — | UBS | Ashwani Verma48% | $83 → $79 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins45% | $77 → $74 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | — | Needham | Ami Fadia62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | — | Needham | Ami Fadia62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | — | Needham | Ami Fadia62% | $94 → $100 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | — | UBS | Ashwani Verma48% | $85 → $83 | Downgrade | Buy → Neutral | Get Alert |
| 06/25/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $103 → $103 | Reiterates | Outperform → Outperform | Get Alert |
| 06/21/2024 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $96 → $100 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $107 → $113 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | — | Needham | Ami Fadia62% | $90 → $94 | Maintains | Buy | Get Alert |
| 06/14/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $120 → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | JP Morgan | Jessica Fye67% | $75 → $78 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | Ami Fadia62% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Ami Fadia62% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $120 → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2024 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $100 → $107 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | — | Needham | Ami Fadia62% | $82 → $90 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $82 → $96 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins45% | $67 → $77 | Maintains | Neutral | Get Alert |
| 04/17/2024 | Buy Now | — | B of A Securities | Jason Gerberry62% | $82 → $91 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | — | Baird | Joel Beatty69% | $83 → $103 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | — | TD Cowen | Joseph Thome34% | $80 → $90 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | — | Needham | Ami Fadia62% | $82 → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Needham | Ami Fadia62% | $82 → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $86 → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $86 → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $101 → $101 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $101 → $100 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | — | Needham | Ami Fadia62% | $72 → $82 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $76 → $82 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | — | RBC Capital | Brian Abrahams52% | $86 → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 01/18/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins45% | $58 → $64 | Maintains | Neutral | Get Alert |
| 01/03/2024 | Buy Now | — | Baird | Joel Beatty69% | → $83 | Initiates | → Outperform | Get Alert |
| 01/02/2024 | Buy Now | — | B of A Securities | Ashwani Verma48% | $74 → $82 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $101 → $101 | Reiterates | Overweight → Overweight | Get Alert |
| 12/11/2023 | Buy Now | — | TD Cowen | Joseph Thome34% | → $75 | Initiates | → Outperform | Get Alert |
| 11/03/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $77 → $76 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $98 → $101 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | — | Needham | Ami Fadia62% | $71 → $72 | Maintains | Buy | Get Alert |
| 08/22/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | → $98 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung56% | $80 → $80 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $78 → $79 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | — | Needham | Ami Fadia62% | $73 → $72 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | — | Needham | Ami Fadia62% | → $73 | Reiterates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung56% | $80 → $80 | Reiterates | Overweight → Overweight | Get Alert |
| 07/06/2023 | Buy Now | — | Needham | Ami Fadia62% | $70 → $73 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | → $76 | Reiterates | Outperform → Outperform | Get Alert |
| 06/05/2023 | Buy Now | — | JP Morgan | Jessica Fye67% | $58 → $62 | Maintains | Overweight | Get Alert |
| 05/08/2023 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $74 → $76 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $72 → $76 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $87 → $90 | Maintains | Overweight | Get Alert |
| 04/21/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung56% | → $80 | Reiterates | → Overweight | Get Alert |
| 04/20/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung56% | → $80 | Initiates | → Overweight | Get Alert |
| 04/18/2023 | Buy Now | — | Needham | Ami Fadia62% | → $66 | Maintains | Buy | Get Alert |
| 03/30/2023 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $66 → $74 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | $83 → $87 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | — | B of A Securities | Ashwani Verma48% | $62 → $63 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | Canaccord Genuity | Sumant Kulkarni43% | $93 → $98 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $66 → $74 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | Needham | Ami Fadia62% | → $66 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | — | JP Morgan | Jessica Fye67% | $59 → $58 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | — | RBC Capital | Brian Abrahams52% | $75 → $71 | Maintains | Outperform | Get Alert |
| 03/02/2023 | Buy Now | — | Needham | Ami Fadia62% | $70 → $66 | Maintains | Buy | Get Alert |
| 03/01/2023 | Buy Now | — | Needham | Ami Fadia62% | → $70 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | — | Needham | Ami Fadia62% | → $70 | Reiterates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan73% | → $83 | Reiterates | → Overweight | Get Alert |
| 08/22/2022 | Buy Now | — | Goldman Sachs | Corinne Jenkins45% | $64 → $49 | Downgrade | Buy → Neutral | Get Alert |
| 08/11/2022 | Buy Now | — | Mizuho | Graig Suvannavejh54% | $75 → $72 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | — | RBC Capital | Brian Abrahams52% | $71 → $70 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | — | Needham | Ami Fadia62% | $65 → $67 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | — | Mizuho | Graig Suvannavejh54% | → $74 | Initiates | → Buy | Get Alert |
| 06/14/2022 | Buy Now | — | UBS | Ashwani Verma48% | → $75 | Initiates | → Buy | Get Alert |
| 04/22/2022 | Buy Now | — | Piper Sandler | Charles Duncan73% | → $59 | Initiates | → Neutral | Get Alert |
| 04/21/2022 | Buy Now | — | SVB Leerink | Marc Goodman73% | $65 → $70 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Intra-Cellular Therapies (ITCI) stock?
The latest price target for Intra-Cellular Therapies (NASDAQ:ITCI) was reported by Mizuho on February 24, 2025. The analyst firm set a price target for $132.00 expecting ITCI to rise to within 12 months (a possible 0.17% upside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intra-Cellular Therapies (ITCI)?
The latest analyst rating for Intra-Cellular Therapies (NASDAQ:ITCI) was provided by Mizuho, and Intra-Cellular Therapies downgraded their neutral rating.
When was the last upgrade for Intra-Cellular Therapies (ITCI)?
The last upgrade for Intra-Cellular Therapies Inc happened on September 6, 2024 when Piper Sandler raised their price target to $92. Piper Sandler previously had a neutral for Intra-Cellular Therapies Inc.
When was the last downgrade for Intra-Cellular Therapies (ITCI)?
The last downgrade for Intra-Cellular Therapies Inc happened on February 24, 2025 when Mizuho changed their price target from $140 to $132 for Intra-Cellular Therapies Inc.
When is the next analyst rating going to be posted or updated for Intra-Cellular Therapies (ITCI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.
Is the Analyst Rating Intra-Cellular Therapies (ITCI) correct?
While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a downgraded with a price target of $140.00 to $132.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $131.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.